Upcoming event

Tags

Abiraterone, abiraterone acetate, ACP3 PET, Active surveillance, Adjuvant, ADT, Advanced prostate cancer, Alkaline phosphatase, Alternative splicing, Androgen, Androgen deprivation therapy, Androgen pathway blockade, Androgen receptor inhibitor, Antiandrogens, Anticancer agents, apalutamide, ARCHES, Article of the Month, artificial intelligence, ASCO GU21, ASCO GU22, ASCO2026, ASCO21, ASCO26, AUA21, BHC80, Biochemical recurrence, biomarker, Biomarkers, Biopsy, Bisphosphonates, Bone metastases, BRCA1, BRCA2, CAPItello-281, capivasertib, Castrate-resistanter, Castration-resistant, Chemotherapy, Clinical trial, Clinical trials, Cohort study, COVID-19, cSP, darolutamide, Deferred treatment, Diagnosis, Disease progression, Docetaxel, EAU21, EAU22, Emission-computed, EMUC21, EMUC22, End-to-side nerve grafting, Enzalutamide, Erectile dysfunction, Erectile function, ESMO21, ESMO22, ESOU Online, ESU Masterclass, ESU Masterclasses, External beam radiotherapy, Focal therapy, Frozen section, Fusion biopsies, Genomic classifier, Genomics, Guidelines, high-risk prostate cancer, homologous recombination repair, hormone-sensitive, HORRAD, HRQL, HRR-deficient mCSPC, Image guided biopsy, Imaging, Immunohistochemistry, Index lesion, Indocyanine green, Intensity-modulated radiotherapy, Local radiotherapy, Localised, Localized, Localized prostate cancer, locally advanced prostate cancer, Lymph node excision, Lymphadenectomy, Mapping, Mass spectrometry, Masterclass, Masterclasses, mCSPC, MDV3100, Membranous urethra, Meta-analysis, Metastasis, Metastasized, Metastatic, metastatic castration-sensitive prostate cancer, metastatic hormone-sensitive prostate cancer, mHSPC, Mortality reduction, mp-MRI, MRI, Neoplasm staging, Nerve sparing, Next-generation sequencing, Nomogram, Noncastrate, Orchiectomy, Overdiagnosis, p53, Patient information, PCa21, PEACE-1 trial, pelvic lymph node dissection, Penile rehabilitation, PET/CT, Positron emission tomography, Precision medicine, prednisone, Pretreatment risk stratification, Pretreatment tables, Primary tumor treatment, PRIMARY2, Prognosis, Prognostic model, Prostasomes, prostate cancer, prostate cancer screening, Prostate screening, Prostate-specific antigen, Prostate-specific membrane antigen, Prostatic neoplasms, ProtecT trial, Proteomics, PROTEUS study, PSA, PSA flare, PSA kinetics, PSA screening, PSMA, PSMA PET/CT, PTEN, PTEN deficiency, Quality of life, Radiation therapy, Radical prostatectomy, radioligand therapy, Randomized prospective trial, Randomized trial, Randomized trials, Rapid metastasis, Rb, RB1, Receptors, Risk stratification, RNA splicing, Robotic prostatectomy, Robotic surgery, Robotic Urology, Robotics, Salvage therapy, Screening, Sentinel lymph node, Sexual quality of life, SREs, SRRM4, STAMPEDE, Stereotactic body radiotherapy, Summer read, Surgical margins, Surgical video, Surgical videos, Systematic biopsy, Systematic review, TALAPRO-3 study, talazoparib, Targeted Biopsy, TITAN, TP53, Transcriptome, Transperineal template biopsy, Tumor suppressor genes, Ultrasensitive PSA, Urinary incontinence, Urological surgery, UROonco25, Urowebinar, WCRF/AICR CUP, Webinar, Wnt, Zoledronic acid
Show all

Long-term oncological and functional follow-up in low dose rate brachytherapy (LDR-BT) for prostate cancer: results from the prospective nation-wide Swiss Registry

BJU International, January 2020

High-intensity focused ultrasound for the treatment of prostate cancer: a national cohort study focusing on the development of stricture and fistulae

European Urology Focus, January 2020

Evaluation of pain in office based transperineal targeted prostate biopsy under local anesthesia using a modified anesthetic protocol

Effect of a behavioral intervention to increase vegetable consumption on cancer progression among men with early-stage prostate cancer: the MEAL randomized clinical trial

JAMA., January 2020

Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study

Lancet Oncology, January 2020

Long-Term outcomes of active surveillance for prostate cancer – the memorial sloan kettering cancer center experience

Journal of Urology, December 2020

Sequencing of androgen-deprivation therapy with external-beam radiotherapy in localized prostate cancer: A phase III randomized controlled trial

Journal of Clinical Oncology, December 2019

Patient-Reported functional outcomes after hypofractionated or conventionally fractionated radiation for prostate cancer: A national cohort study in england

Journal of Clinical Oncology, January 2020

Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received

European Urology, November 2019

Intraoperative frozen section for margin evaluation during radical prostatectomy: A systematic review

European Urology Focus, November 2019

Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up

European Urology, October 2019

The Phoenix criteria for biochemically recurrent prostate cancer after curative radiotherapy appear obsolete in the era of prostate-specific membrane antigen PET: A plea for urgent re-evaluation of current guidelines

November 2019

PreviousNext